Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease

Overview of attention for article published in New England Journal of Medicine, March 2017

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (99th percentile)
High Attention Score compared to outputs of the same age and source (99th percentile)

Mentioned by

news: 215 news outlets
blogs: 25 blogs
policy: 4 policy sources
twitter: 758 X users
patent: 26 patents
facebook: 48 Facebook pages
wikipedia: 5 Wikipedia pages

googleplus: 8 Google+ users
reddit: 35 Redditors
f1000: 1 research highlight platform
q&a: 1 Q&A thread
video: 9 YouTube creators
guideline: 40 clinical guideline sources
podcasts: 14 podcasts

Readers on

mendeley: 3119 Mendeley
citeulike: 1 CiteULike

So far, Altmetric has seen 8 Google+ posts from 8 users.

peter rotzen, 07 Feb 2018

Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease | NEJM Original Article from The New England Journal…

alirio osorio garcía, 12 Aug 2017

Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease — NEJM Original Article from The New England Journal…

rodolfo catanho, 03 May 2017

patients with atherosclerotic cardiovascular disease benefit from lowering of LDL cholesterol levels... patients with…

20 Mar 2017

Genome-based cholesterol drug boosts heart health. In a new, huge study (n=27K), a drug called evolocumab... Genome-based…

This page shows the most recent Google+ posts that mention this research output. Click here to find out how to access more activity, including 4 additional Google+ posts.